September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
FDA Posts Warning on Compounded Semaglutide Products, Citing Reports of Adverse Events
Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.
Friday's 5 Quotes for Primary Care 6-2-2023
The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.
Diabetes Associated with Higher Risk of Death in Persons Hospitalized with Acute Myocardial Infarction
After an acute myocardial infarction, adults with diabetes were over 50% more likely to die after 1 year than those without diabetes, a new study shows.
Daily Dose: Subclinical CVD Affects 1 in 3 US Adults with Diabetes
Your daily dose of clinical news you may have missed.
One in 3 US Adults with T2D Shows Evidence of Subclinical CVD Based on Cardiac Biomarkers
As indicated by levels of 2 common biomarkers of cardiac injury, 33.4% of US adults with T2D showed evidence of undetected CVD vs only 16.1% of those without T2D.
Daily Dose: Disparities in Diabetes Care
New Study Highlights Disparities in Diabetes Care between Urban, Rural Patients
New study found that patients living in urban areas were more likely to meet all aspects of key metrics of diabetes care.
Daily Dose: Rise in Diabetes-Related Vascular Deaths Linked to Renal Complications
FDA Grants Dapagliflozin Label Expansion for Treatment of Full Spectrum of Heart Failure
The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.
Renal Complications Drive Increase in Deaths Related to Vascular Complications in Adults with Diabetes
AACE 2023. Deaths among persons with diabetes in the US related to vascular complications increased from 2001 to 2020, primarily driven by renal complications.
Investigational Antiobesity Drug from Boehringer Ingelheim Meets Primary Endpoint in Phase 2 Trial
The dual GIP/GLP-1 receptor agonist was associated with a nearly 15% reduction in body weight in adults with overweight/obesity and without type 2 diabetes.
Daily Dose: AACE Updates Algorithm for Type 2 Diabetes Management
Start Low, Go Slow with GLP-1 Receptor Agonists when Initiating Weight Management Therapy
GLP-1 RA side effects such as nausea and vomiting can be minimized by starting at the lowest available dose and titrating slowly; Dr Caroline Apovian explains why.
Antiobesity Medications Complement Lifestyle Change in Chronic Weight Management
GLP-1 receptor agonist-based medications for obesity modify gut hormone imbalances, making diet and lifestyle change far more effective, explains Caroline Apovian, MD.
AACE Releases Updated Algorithm for Managing Persons with Type 2 Diabetes
The 2023 algorithm emphasizes a complication-centric approach, beyond glucose levels, for determining first-line pharmacotherapy.
Novel 1-hour Endoscopic Procedure Could Eliminate Need for Insulin in Patients with T2D
The novel ablation technique which "rejuvenates" critical duodenal mucosa, is followed after 2 weeks by treatment with semaglutide and was both safe and effective.
ACP Announces Intensified Advocacy for Equitable Care of Obesity
The American College of Physicians announced an initiative that renews and expands its focus on equitable access to obesity care, including new resources for physicians.
Metabolic Syndrome and Poor Fitness in Women Increase Long-term CVD Risk: New Research
Women with ischemic heart disease who were metabolically unhealthy but fit were more than 50% more likely to experience a major adverse cardiovascular event.
FDA Clears Omnipod GO Insulin Delivery Device for Persons with Type 2 Diabetes
The wearable tubeless insulin delivery device provides a fixed rate of continuous long-acting insulin for 72 hours, requiring no needles or injections.
Bariatric Surgery Associated with NASH Resolution in Randomized, Open-label Trial
In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.
Beverage Choice May Help Reduce Mortality, CVD in Adults with Type 2 Diabetes, Findings Suggest
Higher intake of sugar-sweetened drinks was linked to increased risk of all-cause death and CVD while healthier choices were inversely associated with both, a new study found.
Clopidogrel Superior to Aspirin for Long-term Antiplatelet Monotherapy After PCI
Friday's 5 Quotes for Primary Care 3-31-2023
Screening for diabetes by weight will increase diagnoses; weight regain after loss doesn't cancel health benefits; strategy tested to improve RSV detection; and 2 more studies of note.
Daily Dose: Reversion from Prediabetes to Normoglycemia & Mortality Risk
Reversing Prediabetes Without Lifestyle Change May Not Reduce Mortality Risk: Study
Among persons with prediabetes who reverted to normoglycemia, only those who remained physically active saw a reduced risk of all-cause death, study authors report.
Weight Regain May Not Fully Diminish Benefits of Weight Loss on Cardiometabolic Health
A new study examines the legacy effects of weight loss on cardiometabolic disease risk factors, finding benefits persist up to 5 years, despite weight regain.
Screening for Diabetes by Age vs by Weight Could Reduce US Health Disparities, Suggests a New Study
The disproportionate prevalence of undiagnosed diabetes among racial/ethnic minorities in the US begs for a new screening paradigm; this may be the one.
Sanofi Third Insulin Maker to Announce Price Reductions Across Brands
Sanofi is the third key insulin maker to announce reductions in the cost of its products, joining other giants Eli Lilly and Co and Novo Nordisk.
Novo Nordisk Announces 2024 Price Cut for Insulin Products
The announcement follows by 2 weeks a similar plan from Eli Lilly to reduce patient costs as the Biden administration touts effects of new laws on drug prices.
Artificial Pancreas Improves Time in Range for Young Children with Type 1 Diabetes, According to New Study
Young children using a hybrid closed-loop insulin delivery system spent 12% more time within their target blood glucose range than those who received standard care, according to new research.